{
    "relation": [
        [
            "",
            "Operating margin (%)",
            "Net-margin (%)",
            "ROE (%)",
            "ROA (%)",
            "ROC (Joel Greenblatt) (%)",
            "Revenue Growth (3Y)(%)",
            "EBITDA Growth (3Y)(%)",
            "EPS Growth (3Y)(%)"
        ],
        [
            "",
            "12.51",
            "26.98",
            "23.27",
            "10.85",
            "98.23",
            "-2.40",
            "19.10",
            "26.30"
        ],
        [
            "vs industry",
            "MRK's Operating margin (%) is ranked higher than 64% of the 658 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 7.76 vs. MRK: 12.51 ) Ranked among companies with meaningful Operating margin (%) only.",
            "MRK's Net-margin (%) is ranked higher than 92% of the 659 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 5.90 vs. MRK: 26.98 ) Ranked among companies with meaningful Net-margin (%) only.",
            "MRK's ROE (%) is ranked higher than 85% of the 685 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 6.19 vs. MRK: 23.27 ) Ranked among companies with meaningful ROE (%) only.",
            "MRK's ROA (%) is ranked higher than 78% of the 705 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 3.10 vs. MRK: 10.85 ) Ranked among companies with meaningful ROA (%) only.",
            "MRK's ROC (Joel Greenblatt) (%) is ranked higher than 92% of the 703 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 11.97 vs. MRK: 98.23 ) Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.",
            "MRK's Revenue Growth (3Y)(%) is ranked lower than 75% of the 541 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 5.80 vs. MRK: -2.40 ) Ranked among companies with meaningful Revenue Growth (3Y)(%) only.",
            "MRK's EBITDA Growth (3Y)(%) is ranked higher than 74% of the 483 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 6.80 vs. MRK: 19.10 ) Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.",
            "MRK's EPS Growth (3Y)(%) is ranked higher than 79% of the 451 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 5.40 vs. MRK: 26.30 ) Ranked among companies with meaningful EPS Growth (3Y)(%) only."
        ],
        [
            "vs history",
            "MRK' s 10-Year Operating margin (%) Range Min: 5.15 Med: 22.79 Max: 43.77 Current: 12.51 5.15 43.77",
            "MRK' s 10-Year Net-margin (%) Range Min: 1.87 Med: 19.58 Max: 47.03 Current: 26.98 1.87 47.03",
            "MRK' s 10-Year ROE (%) Range Min: 1.51 Med: 33.15 Max: 48.6 Current: 23.27 1.51 48.6",
            "MRK' s 10-Year ROA (%) Range Min: 0.79 Med: 15.50 Max: 18.45 Current: 10.85 0.79 18.45",
            "MRK' s 10-Year ROC (Joel Greenblatt) (%) Range Min: 10.88 Med: 66.49 Max: 144.19 Current: 98.23 10.88 144.19",
            "MRK' s 10-Year Revenue Growth (3Y)(%) Range Min: -16.5 Med: 3.60 Max: 21.4 Current: -2.4 -16.5 21.4",
            "MRK' s 10-Year EBITDA Growth (3Y)(%) Range Min: -17.6 Med: 3.80 Max: 44.7 Current: 19.1 -17.6 44.7",
            "MRK' s 10-Year EPS Growth (3Y)(%) Range Min: -42.7 Med: 6.70 Max: 73.8 Current: 26.3 -42.7 73.8"
        ]
    ],
    "pageTitle": "Merck & Co Inc (MRK) Stock Analysis - GuruFocus.com",
    "title": "",
    "url": "http://www.gurufocus.com/stock/MRK&GuruName=Brian+Rogers&focusbar=1",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 3,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989043.35/warc/CC-MAIN-20150728002309-00046-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 487799487,
    "recordOffset": 487759199,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Financial Strength : 7/10 }); }); tip : '#rank_balancesheet_tools' position : \"top right\", $(\"#rank_balancesheet_bar\").tooltip({ $(function() { ); } }); delay : 500 tip : '#yield_on_cost_indu_tools', offset: [10, 0], relative: true, position : \"top left\", $(\"#yield_on_cost_indu\").tooltip({ }); delay : 500 tip : '#yield_on_cost_tools', offset: [10, 0], relative: true, position : \"top left\", $(\"#yield_on_cost_bar\").tooltip({ }); delay : 500 tip : '#total_buyback_3y_indu_tools', offset: [10, 0], relative: true, position : \"top left\", $(\"#total_buyback_3y_indu\").tooltip({ }); delay : 500 tip : '#total_buyback_3y_tools', offset: [10, 0], relative: true, position : \"top left\", $(\"#total_buyback_3y_bar\").tooltip({ }); delay : 500 tip : '#dividend_growth_3y_indu_tools', offset: [10, 0], relative: true, position : \"top left\", $(\"#dividend_growth_3y_indu\").tooltip({ }); delay : 500 tip : '#dividend_growth_3y_tools', offset: [10, 0], relative: true, position : \"top left\", $(\"#dividend_growth_3y_bar\").tooltip({ }); delay : 500 tip : '#payout_indu_tools', offset: [10, 0], relative: true, position : \"top left\", $(\"#payout_indu\").tooltip({ }); delay : 500 tip : '#payout_tools', offset: [10, 0], relative: true, position :",
    "textAfterTable": "0.79 18.45 ROC (Joel Greenblatt) (%) 98.23 MRK's ROC (Joel Greenblatt) (%) is ranked higher than 92% of the 703 Companies in the Global Drug Manufacturers - Major industry. ( Industry Median: 11.97 vs. MRK: 98.23 ) Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only. MRK' s 10-Year ROC (Joel Greenblatt) (%) Range Min: 10.88 \u00a0Med: 66.49\u00a0Max: 144.19 Current: 98.23",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}